Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies

This publication has 33 references indexed in Scilit:

• PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
  Cancer Discovery, 2012
• Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
  Journal of Oncology, 2012
• Molecular approaches to personalizing management of ovarian cancer
  Annals of Oncology, 2011
• ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
  Cancer Research, 2011
• Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
  Human Mutation, 2011
• The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
  British Journal of Cancer, 2011
• ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
  New England Journal of Medicine, 2010
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
  The Journal of Pathology, 2010
• KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay
  BMC Cancer, 2009
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996